This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Budd, G. T. Articles by Weick, J. Search for Related Content PubMed PubMed Citation Articles by Budd, G. T. Articles by Weick, J.

Phase I Trial of Dipyridamole with 5-Fluorouracil and Folinic Acid

The Cleveland Clinic Foundation, Cleveland, Ohio 44195 [G. T. B., D. G., D. A., L. B., J. B., R. B., S. M., J. W.], and Boehringer-Ingleheim Pharmaceuticals, Ridgefield, Connecticut [A. J.]

We have performed two Phase I trials of the combination of dipyridamole, 5-fluorouracil (5-FU), and folinic acid in patients with advanced refractory malignancy, based upon in vitro evidence that dipyridamole can modulate the cytotoxicity of 5-FU. In the first trial, patients were treated every 4 wk with dipyridamole (50 mg/m²) p.o. every 6 h on Days 0 to 6, beginning 24 h prior to the i.v. administration of folinic acid (200 mg/m²) and escalating doses of i.v. 5-FU on Days 1 to 5. The maximum tolerated daily dose of 5-FU that could be given with this combination was 375 mg/m². Because dipyridamole is extensively bound to plasma proteins, it was hypothesized that the concentrations of free dipyridamole achieved with a dose of 50 mg/m² were inadequate to modulate the cytotoxicity of 5-FU and folinic acid. Therefore, a second Phase I trial of escalating dose of p.o. dipyridamole was performed. Folinic acid (200 mg/m²) and 5-FU (375 mg/m²) were given i.v. on Days 1 to 5 every 4 wk, beginning 24 h after the start of therapy with dipyridamole; dipyridamole was administered p.o. on Days 0 to 6 at doses of 75, 100, 125, 150, 175, or 200 mg/m²/dose to successive cohorts of patients. Dose-limiting neutropenia, mucositis, and nausea were produced at a dose of 200 mg/m²/dose; the recommended dose of dipyridamole for use in Phase II studies is 175 mg/m² p.o. every 6 h, or 700 mg/m²/day. At this dose, a mean peak plasma concentration of total dipyridamole of 16.32 µmol and a mean peak plasma concentration of free dipyridamole of 38.30 nmol were observed. Trough concentrations of free dipyridamole averaged 60% of the peak concentrations. Objective antitumor responses were seen in a number of tumor types; five of 13 patients with breast cancer treated with high-dose p.o. dipyridamole, 5-FU, and folinic acid responded. High-dose p.o. dipyridamole can produce plasma concentrations of free dipyridamole within the range shown to modulate the cytotoxicity of 5-FU and other agents. Phase II trials of this combination are justified.

¹ To whom requests for reprints should be addressed, at Department of Hematology and Medical Oncology, Cleveland Clinic, One Clinic Plaza, 9500 Euclid Avenue, Cleveland, OH 44195.

Received 5/17/90. Accepted 8/17/90.

This article has been cited by other articles:

				H. D. Thomas, K. Saravanan, L.-Z. Wang, M.-J. Lin, J. S. Northen, H. Barlow, M. Barton, D. R. Newell, R. J. Griffin, B. T. Golding, et al. Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity Mol. Cancer Ther., July 1, 2009; 8(7): 1828 - 1837. [Abstract] [Full Text] [PDF]

				P. G. Smith, H. D. Thomas, H. C. Barlow, R. J. Griffin, B. T. Golding, A. H. Calvert, D. R. Newell, and N. J. Curtin In Vitro and in Vivo Properties of Novel Nucleoside Transport Inhibitors with Improved Pharmacological Properties That Potentiate Antifolate Activity Clin. Cancer Res., July 1, 2001; 7(7): 2105 - 2113. [Abstract] [Full Text] [PDF]

				D. H. Patel, J. A. Allay, J. A. Belt, and B. P. Sorrentino Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells Blood, April 1, 2000; 95(7): 2356 - 2363. [Abstract] [Full Text] [PDF]

				M. Hejna, M. Raderer, and C. C. Zielinski Inhibition of Metastases by Anticoagulants J Natl Cancer Inst, January 6, 1999; 91(1): 22 - 36. [Abstract] [Full Text] [PDF]